2L Phase 3 study of MK2870 + platinum vs. MK2870 vs. platinum doublets in EGFR mutant advanced NSCLC patients progressed on prior EGFR TKls

This trial is testing MK-2870 (sacituzumab tirumotecan, also called sac-TMT) in people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. This is called advanced NSCLC. MK-2870 is an experimental drug. It has not been approved by the U.S. Food and Drug Administration (FDA) to treat any type of cancer. This trial will compare MK-2870 to pemetrexed and carboplatin. Pemetrexed given with carboplatin is one of the standard chemotherapy combinations approved by the FDA to treat advanced NSCLC.

Protocol#: MERCK-MK2870-009